Table 4.
Clinical outcomes across bilirubin quartiles.
| Overall | Q1 | Q2 | Q3 | Q4 | p-value | |
|---|---|---|---|---|---|---|
| (n = 5,322) | (n = 1,231) | (n = 1,188) | (n = 1,440) | (n = 1,463) | ||
| Death | 901 (16.9) | 181 (14.7) | 171 (14.4) | 266 (18.5) | 283 (19.3) | <0.001 |
| Cardiac death | 471 (8.9) | 94 (7.6) | 89 (7.5) | 139 (9.7) | 149 (10.2) | 0.025 |
| MI | 315 (5.9) | 83 (6.7) | 66 (5.6) | 87 (6.0) | 79 (5.4) | 0.470 |
| Revascularization | 462 (8.7) | 111 (9.0) | 115 (9.7) | 116 (8.1) | 120 (8.2) | 0.423 |
| Stroke | 395 (7.4) | 93 (7.6) | 93 (7.8) | 102 (7.1) | 107 (7.3) | 0.900 |
| MACCE | 1,777 (33.4) | 385 (31.3) | 382 (32.2) | 502 (34.9) | 508 (34.7) | 0.119 |
MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.